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Bormal Valves: Development and Structure
ormal human semilunar valve development. Ninety-
ne semilunar valves from fetuses, neonates, children, and
dults were studied (1). Valvular endothelial cells express an
ctivated phenotype throughout gestation. Valvular intersti-
ial cell density, proliferation, and apoptosis are higher in
etal than adult valves indicating matrix remodeling whereas
n adults it is a quiescent fibroblast-like phenotype (Fig. 1).
lastin significantly increases postnatally (Fig. 2). The
uthors concluded: “Fetal valves possess a dynamic/adaptive
tructure and contain cells with an activated/immature
henotype. During postnatal life, activated cells gradually
ecome quiescent, whereas collagen matures.”
amilial Aggregation of
alcific Aortic Stenosis (AS)
he geographic distribution of 2,527 operated patients with
alcific AS was heterogeneous in areas in France, with
requencies of 1.13 to 9.38 of 1,000 inhabitants in different
arishes (Fig. 3). From parishes with the highest rate of
perated AS, there were 5 families in whom 3 siblings
ere affected. Genealogical examination traced a common
ncestor within 13 generations in one of the families in
hom 48 patients were derived from 34 nuclear families (2).
omment. These findings suggest a genetic component to
alcific AS in some patients. An earlier study had shown the
amilial relative risk of death per year in those aged 65
ears was 4 times higher in first degree relatives of those
ith aortic valve (AV) disease documenting a heritable
omponent (3).
rom the Griffith Center, Division of Cardiovascular Medicine, Department of
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006, accepted November 6, 2006.echanisms of Valvular Heart Disease (VHD)
ow-density lipoprotein receptor-related protein (Lrp5).
ow-density lipoprotein receptor-related protein, osteocal-
in, and other osteochondrogenic differentiation markers are
ncreased in calcified AV by protein and gene expression
p  0.001) (4). Sox9, Lrp5 receptor, and osteocalcin were
ncreased in myxomatous mitral valves (MV) by protein and
ene expression (p  0.001). Microcomputed tomography
as positive in the calcified AV and negative in the
yxomatous MV (Figs. 4 and 5). The authors concluded:
The mechanisms of VHD involve an endochondral bone
rocess that is expressed as cartilage in MV and bone in AV.
p-regulation of the Lrp5 pathway may play a role.”
uman atrial ion channel and transporter subunit gene
xpression. Messenger ribonucleic acid expression was
uantified in atrial tissues from 7 sinus rhythm-VHD, 11
trial fibrillation (AF-VHD), and 11 control subjects (5).
rincipal findings were: VHD produces important changes
n cardiac ion-channel gene expression, discrete ion-channel
ubunit changes differentiate patients with VHD who de-
elop persistent AF from those who do not.
xtravalvular cells in “degenerative” valves. Studies of
S and bioprosthetic valves showed that endothelial pro-
enitor cells, dendritic cells, T-lymphocytes, and macro-
hages were much higher in bioprosthetic than in AS (6)
Table 1).
omment. These findings suggest pathogenetic factors
nvolved in degenerative native and bioprosthetic AS are
robably different.
ell death is autophagic. Calcific AS valves showed much
igher scores of calcification, inflammation, and ubiquiting
abeling than control valves (7). TUNEL-labeled cells were
arely found; thus, the main cell death mechanism in AS is
utophagy rather than apoptosis.
nimals that may develop AS. Apolipoprotein-E-
eficient mice had AV sclerosis (8), which showed bone
arrow-derived cells that were positive for osteoblast-
elated markers near the sites of ectopic calcification.
New Zealand white rabbits with experimental hyperten-
ion developed AV sclerosis (9).
ole of matrix metalloproteinases in human AV disease.
oth AS and aortic regurgitation (AR) showed similar histo-
ogic signs of extracellular matrix remodeling, although calci-
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Year in Valvular Heart Disease January 23, 2007:361–74cation, inflammatory cells, and capillaries were more severe
n AS than in AR. Increases in matrix metalloproteinase-9
nd -3 demonstrated an inflammatory state that was greater
n severe AS (10).
etabolic syndrome (MetS) increases the risk of AV
alcification. Aortic valve calcification was assessed by
lectron beam computed tomography (EBCT) in 6,780
ESA (Multi-Ethnic Study of Atherosclerosis) partici-
ants (MetS [n  1,550], diabetes mellitus [n  1,016], or
either [n 4,024]) free of clinical cardiovascular disease at
Figure 1 Endothelial Cells of Fetal Valves Have an Immature/A
(A) CD31-positive fetal valvular endothelial cells (VECs) in the second and third tri
duced by embryonic or activated cells (SMemb), matrix metalloproteinase (MMP)-1
VECs mostly had negligible expression levels of these proteins. Bar  50 m. Ma
ferences in protein expression in adult valves (p  0.001). From Aikawa et al. (1).aseline. Follow-up showed that the prevalence and the 0djusted relative risk of AV calcification was increased in
etS and with increasing number of MetS components
11) (Table 2).
nfluence of MetS on outcomes in AS. Of 105 patients,
ith mean aortic valve area (AVA) 1.08 followed-up for 28
onths, linearized progression was “twice as fast” (0.14
s. 0.08), 3-year event-free survival was lower (44 vs. 69)
n 40 (38%) with MetS (12). In multivariate analysis, MetS
as an independent predictor of stenosis progression (p 
.006) and event-free survival (odds ratio [OR] 3.85, p 
ted Phenotype
rs and VECs in children’s valves consistently expressed nonmuscle myosin pro-
-13, and cell adhesion molecules ICAM-1 and VCAM-1, whereas normal adult
tion 400. (B) Percent of endothelial cells positive for maker. *Significant dif-ctiva
meste
, MMP
gnifica.001).
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January 23, 2007:361–74 Year in Valvular Heart Diseaseomment. Concerns include: 1) is it appropriate to calcu-
ate annual linearized rate of progression when echocardio-
rams may only have been obtained 6 months apart, there
ere almost no events in the first year indicating non-
inearity and follow-up was 3 years or less?; 2) patients’
linical condition (e.g., symptoms, functional class, left
entricular ejection fraction [LVEF], and so on) at baseline
ere not provided, and 7 of 8 deaths were not related to AS;
) many patients had severe AS at baseline; the reason(s)
hy 45 AV replacements (AVRs) were performed 1 year
ater was not described.
S
alve calcification as marker for severity is inaccurate.
alcification score from EBCT for AV calcium content in
1 patients with AS and AVA of 0.7 to 2.0 cm2 (13)
howed AV Agatston score “did not correlate strongly”
ith AVA (r  0.34, p  0.0007). The poorest
orrelation was noted for those patients with moderate
nd severe AV calcification.
low-dependent changes in AVA are real. An in-vitro
tudy (14) using particle image velocimetry (PIV) in bio-
rosthetic valves showed good agreement with Doppler
DOP)-derived effective orifice area (EOA) (r2  0.94).
hen stroke volume was increased from 20 ml to 70 ml,
here were substantial and similar increases by both meth-
ds: 52% for EOADOP versus 63% for EOAPIV. The
Figure 2 Schematic Representation of Natural History of Cardia
Schematic summary of cardiac valve remodeling in fetal valves according to the fin
ing in gestation were followed after birth by decreased cell activation and eventual
collagen fiber thickness and alignment. Thin lines  thin, immature collagen fibers
in Figure 1.uthors concluded: flow-dependent changes in EOADOP wre real and are due to “unsteady effects” at low flow rates
nd/or to changes in valve leaflet opening.
igh incidence of vascular atherosclerosis in AS. In 282
atients with severe calcific AS, the incidence of severe
bstructive coronary atherosclerosis (59%) and of extracra-
ial cerebral arteries (16%) was significantly associated (p 
.005) (15).
mprovement in LVEF after AVR in low gradient severe
S is not related to “contractile reserve.” In 66 previously
eported patients with preoperative LVEF 0.40, 46 (70%;
roup I) had “contractile reserve” (increase of left ventric-
lar [LV] stroke volume by 20% calculated by echocardi-
graphy/Doppler) and 20 did not (30%; Group II) (16).
fter AVR, LVEF increased by0.10 in 38 (83%) patients
n Group I and in 13 (65%) patients in Group II; mean
ncrease of LVEF was similar in the 2 groups (19 10% vs.
7  11%, p  0.54). On multivariate analysis, LVEF
mprovement was related to multivessel coronary artery
isease, p  0.05 and baseline mean pressure gradient (30
m Hg), p  0.01, but not to contractile reserve.
omment. Uncertain if coronary artery disease was revas-
ularized at time of AVR?
oor outcomes without AVR in older symptomatic pa-
ients. A total of 124, age 60 years (73 of 124, 59% age
80 years) with severe AS (mean AV gradient50 mmHg
r AVA 0.8 cm2) and LVEF 0.50 in 69.9% were
valuated. Forty-nine (39.5%) had AVR, 30-day mortality
lve Remodeling by Interstitial Cells
of the present study. Activated/immature cell phenotypes and collagen remodel-
dults, by quiescence. These cellular changes were accompanied by increased
k lines  thick, mature collagen fibers. From Aikawa et al. (1). Abbreviations asc Va
dings
ly, in a
; thicas 4.1%. At 1 year, survival with AVR versus no AVR in
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Year in Valvular Heart Disease January 23, 2007:361–74he subgroup age 80 years (in whom LVEF 0.50 in
3.9%) was 87.5% versus 49.1%, respectively (p  0.006)
17). Aortic valve replacement was associated with a large
ortality reduction, adjusted OR 0.39 (95% confidence
nterval [CI] 0.22 to 0.67).
omment. Even symptomatic octogenarians with severe
S have a better survival with AVR.
ood outcomes after AVR for severe AS with reduced
VEF. One-hundred fifty-five consecutive patients with
VA 1.0 cm2, LVEF 0.30, age 72  9 years, and New
ork Heart Association (NYHA) functional class III or IV
n 89% underwent AVR (with coronary artery bypass
rafting in 16%, abnormal coronary angiograms in 41%)
18). Operative mortality was 12%. The 5-year survival was
1%; 31 of 50 (62%) patients died of non-cardiac causes;
0% had an increase of LVEF (from 0.25  0.05 to 0.36 
.12). In 45%, LVEF had increased by0.10, those with an
arly increase of LVEF 0.10 had a better 10-year survival
Fig. 6), and at 1 year 3% were in NYHA functional class
II/IV (vs. 89% preoperatively).
omment. After successful AVR, more than half of the
eaths were due to “non-cardiac” causes, and since 89%
ere in NYHA functional class III or IV at baseline, it is
mportant not to wait for severe symptoms before perform-
ng AVR. Improvement of LVEF of 0.10 after AVR was
ssociated with a better 10-year survival, and 97% of the
Figure 3 Map of the Repartition of Operated CAVS in the West
Disease frequency was calculated for each parish by comparing the number of nat
the village. Population was estimated from the mean of the censuses performed i
ters of high frequency can be described, 1 on the northern part of the map and 1
coast and Cholet, corresponding to a well-known isolate called “vendee-cholletaise
identified. From Probst et al. (3).urvivors were asymptomatic or minimally symptomatic 8mphasizing the need to perform AVR before the onset of
oderate/severe LV dysfunction so that postoperatively the
atients will have higher LVEF.
alue of quantitative exercise Doppler echocardiography.
ixty-nine asymptomatic patients age 66  12 years with
evere AS (AVA 1 cm2) underwent quantitative exercise
chocardiography/Doppler (19). Follow-up was 15  7
onths; 18 of 26 (69%) with abnormal response to exercise
ad symptoms, death, or AVR. By multivariate Cox regres-
ion analysis, independent predictors of cardiac events were
n increase of mean AV gradient by 18 mm Hg during
xercise (p 0.0015), an abnormal exercise test (p 0.0026),
nd AVA 0.75 cm2 (p  0.0031). Exercise echocardiogra-
hy/Doppler provided incremental prognostic value over rest-
ng echocardiographic and exercise electrocardiographic
arameters.
unctional mitral regurgitation (MR) improves after
VR. Four hundred eight patients, age 70 years, under-
ent isolated AVR (20); 338 patients had no/mild MR
Group I); 70 had moderate MR (Group II) in whom MR
as functional in 21.4%. On multivariate analysis, moderate
R was an independent risk factor impacting long-term
urvival; in groups I and II, survival at 10 years was 14.6%
ersus 40.1% (p  0.04). Mitral regurgitation worsened or
ersisted in those with intrinsic MV disease but improved in
art of France
ses of operated calcific aortic valve stenosis (CAVS) to the population living in
, 1931, and 1936. This map shows an obvious spatial heterogeneity. Two clus-
en the southern part of Nantes and La Roche-sur-Yon and between the Atlantic
letters represent parishes in which familial aggregation of the disease has beenern P
ive ca
n 1926
betwe
.” The1.8% of those with functional MR.
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ong-term outcome of surgically treated AR. One hun-
red seventy patients with severe isolated chronic AR had
VR between 1982 and 2002 according to predefined
rotocol. Patients were divided into 2 groups depending on
heir clinical situation at the time of surgery. Group A
Figure 4 Immunohistochemistry of the Human Mitral Degenera
Calcified Tricuspid and Bicuspid Aortic Valves for Non
Control valve, degenerative mitral valve (arrow points to hypertrophic chondrocytes
(arrow points to positive stain) (magnification 25). Insert within each photo is hi
sialoprotein strain. (B) Osteoponton stain. (C) Osteocalcin stain. From Caira et al
Figure 5 Immunohistochemistry of the Human Mitral Degenera
Valves for Endochondral Signaling Markers Low-Densi
Control valve, degenerative mitral valve (arrow points to hypertrophic chondrocytes
(arrow points to positive stain) (magnification 25). Insert within each photo is a
Lipoprotein receptor-related protein 5 stain. (B) Wnt 3 stain. (C) Proliferating cell“early” surgery) included asymptomatic patients and those
n NYHA functional class II with “moderate degrees” of LV
ysfunction (LVEFs between and 45% and 50% and/or
nd-systolic diameters between 50 mm and 55 mm). Group
(“too late” surgery) included patients with either severe
ymptoms (NYHA functional classes III and IV) or in
alves and
genous Bone Matrix Synthesis
ified aortic valves (arrow points to positive stain), and bicuspid aortic valve
er magnification to demonstrate cellular staining (magnification 40) (A) Bone
alves and Calcified Tricuspid and Bicuspid Aortic
ceptor Protein 5/Wnt and Proliferating Cell Nuclear Antigen
ified aortic valves (arrow points to positive stain), and bicuspid aortic valve
wer magnification to demonstrate cellular staining (magnification 40). (A)
r antigen strain. From Caira et al. (4).tive V
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Year in Valvular Heart Disease January 23, 2007:361–74YHA functional class I/II with an LVEF45% or an LV
nd-systolic diameter 55 mm (21).
One hundred seventy patients were age 50  14 years
hose 45 years had normal coronary angiograms.
ollow-up was 10  6 years (1 to 22 years). Survival up to
2 years was significantly better in Group A patients. Both
roups showed significant increases in LVEF, reductions in
V end-diastolic diameter and LV end-systolic diameter,
nd improvement in NYHA functional class (Table 3). The
uthors concluded: “Early operation as defined in the
uidelines improves long-term survival in patients with
hronic AR.”
omment. A clinically valuable study with the longest
ocumented follow-up data. It started many years before
ny “guidelines” and thus is a prospective study with patients
aving had care delivered by a single cardiologist (P.T.) who
s a highly experienced and well known cardiologist. When
atients were analyzed only by NYHA functional class, the
ndings were similar to what was previously well known
ith regard to NYHA and LV systolic function (22,23).
abeling Group B as “too late” is potentially misleading
ecause they also had benefit in NYHA functional class, LV
imensions, and LVEF. It would be more appropriate to
abel them as “later” surgery.
andomized trial of vasodilators (“Barcelona trial”).
inety-five asymptomatic patients with normal LV func-
ion were randomized in an open-label trial of angiotensin-
onverting enzyme inhibitor, nifedipine, or placebo (24).
Extravalvular Cells in “Degenerative” Valves
Table 1 Extravalvular Cells in “Degenerative
Aortic Stenosis (n
Cell Bound Signals F
EPC
CD 34 48%
CD 133 58%
DC
100 58%
Inflammatory cells
T-lymphocytes (CD3) 62%
Macrophages (CD68) 78%
*p  0.001 versus aortic stenosis. Data from Skowasch et al. (6).
DC  dendritic cells; EPC  endothelial progenitor cells.
revalence of AVC in MESA
Table 2 Prevalence of AVC in MESA
Women Men
Metabolic syndrome 17% 24%
Diabetes mellitus 12% 22%
Neither 8% 14%
p Value 0.001 0.001
Adjusted RR of AVC*
Metabolic syndrome 1.45 (1.11–1.90) 1.7 (1.32–2.19)
Diabetes mellitus 2.12 (1.54–2.94) 1.73 (1.33–2.25)
Compared to neither. Data from Katz et al. (11).c
AVC aortic valve calcification; MESAMulti-Ethnic Study of Atherosclerosis; RR relative risk
95% confidence interval).fter a mean follow-up of 7 years, there was no statistically
ignificant outcome difference between the 3 groups.
omment. There are several concerns with this trial (25):
) the mean (SD) of diastolic blood pressure in the
ifedipine group was 78  11 mm Hg. In patients with
hronic severe AR, this measure is very much lower, which
uggests that most patients in the nifedipine group did not
ave severe AR. Moreover, the LV end-diastolic volume
ndex was 94  27 ml/m2, whereas in the Padua trial it was
26  16 ml/m2 (26), which supports that many patients in
he Barcelona trial did not have chronic severe AR; 2) there
ere 32 patients in the nifedipine arm, 7 (22%) dropped out
t 2 7 months, thus, only a small number of patients were
andomized. In the Padua trial there were 69 patients in the
ifedipine group and 4 were lost to follow-up; and 3) there
as no change in blood pressure in the Barcelona trial in
hich nifedipine 20 mg twice a day was given. In the Padua
rial, long-acting nifedipine 20 mg was given twice a day,
nd at the end of the trial there were significant reductions
f LV volumes and increase of LVEF; in the Barcelona trial
here were no significant changes in LV volumes or in
VEF.
urgery in Takayasu Arteritis. Sixty-three of 90 (70%)
atients had AVR (Group A) and 27 (30%) had composite
raft repair (Group B). The aortic root diameters in Groups
and B were 39.9  9.5 mm and 54.4  13.6 mm,
espectively, p  0.001 (27). Survival rate at 15 years was
6.1%.
icuspid AV
alve preservation and repair for AR. Aortic valve repair
as performed for bicuspid AV  AR in 71 patients, age
1.5  13.2 years (28). Additional procedures were per-
ormed in many patients. Four patients were reoperated for
ecurrent AR. There were no operative deaths and 1
erioperative stroke. At 8 years, the survival was 96.7%, and
he incidence of 3  AR at 8 years was 55.8  10%.
omment. The high rate of severe AR at 8 years is of
lves
Bioprosthesis (n  27)
ncy (%) Cell Bound Signals Frequency (%)
13.0 74% 19.2 23.2*
8.3 81% 13.7 12.4*
8.9 93% 15.2 2.2*
1.4 81% 3.3 2.7*
4.1 93% 35.3 26.6*” Va
 60)
reque
5.7
5.5
5.7
1.1
3.4oncern.
ML
A
0
1
w
v
(
M
T
s
w
(
s
w
r
h
I
p
(
0
(
w
w
O
S
h
m
o
o
f
p
F
T
M
a
2
a
s
h
C
g
p
f
d
o
a
S
r
s
q
h
f
n
3
C
b
o
i
367JACC Vol. 49, No. 3, 2007 Rahimtoola
January 23, 2007:361–74 Year in Valvular Heart Diseaseitral Stenosis
ong-term results of catheter balloon commissurotomy.
total of 493 patients, age 31 11 years, were followed for
.5 to 15 years. At 5, 10, and 13 years, restenosis rates were
 1%, 32 3%, and 49 6% and event-free survival rates
ere 92  1%, 80  3%, and 74  3%, respectively. Mitral
alve echocardiographic score 8 (p  0.0003) and age
p  0.004) were predictors of event-free survival (29).
R: MV Prolapse (MVP), Flail Leaflet (F-L)
hird chromosomal locus for MVP. Genotypic analyses
howed evidence of linkage on chromosome 13q 31.3-32.1q
ith peak parametric linkage score of 18.41 (p  0.0007)
30). Multipoint parametric analysis gave a logarithm odd
core of 3.17 at marker D13S132. Of 6 related individuals
ith MV, morphologies not meeting diagnostic criteria but
esembling fully developed forms, 5 carried all or part of the
aplotype linked to MVP.
maging planes to assess localization of MVP or F-L. In
atients with MVP/F-L, transthoracic echocardiography
TTE) was accurate with surgical findings in 91% (Kappa
.81) and 93% for transesophageal echocardiography
TEE). Mitral valve replacement (MVR) predicted by TTE
as an independent predictor for postoperative mortality
ith OR 5.7; 95% CI 1.97 to 16.4, p  0.001 (31).
ptimal timing of MV repair (MVrep): the Vienna
tudy. One hundred thirty-two consecutive patients, 74
ad MVP, 58 had F-L, were prospectively followed for 62
onths (32). Patients were referred for surgery: 1) at onset
f symptoms; or 2) asymptomatic but developed 1 or more
Figure 6 Actuarial Survival of Patients With Early Increase of E
EF  left ventricular ejection fraction; EFU  ejection fraction units. From Vaquettef LV end-systolic diameter 45 mm or 26 mm/m2, Mractional shortening  26 mm/m2, LVEF 0.60, systolic
ulmonary artery pressure 50 mm Hg, or recurrent AF.
ollow-up was 98% complete, median was 69.2 months.
here were 8 deaths (3 in patients with F-L and 5 with
VP); 1 patient who had refused surgery, 1 while still
symptomatic, 1 of myocarditis, 1 of stroke, 2 of cancer, and
postoperative. Survival (Table 4) and event-free survival
re shown in Figures 7A and 7B. Of 35 patients who had
urgery, 23 (82.9%) had MVrep; 23 were asymptomatic, 12
ad mild symptoms.
omment. A very important study. It documents very
ood patient outcomes up to 8 years in asymptomatic
atients with degenerative severe MR if MVrep is per-
ormed: 1) with the development of even mild symptoms
uring close clinical follow-up; and 2) with the appearance
f predetermined objective criteria. Performing MVR in the
symptomatic patient is of some concern.
urgical MVrep. Alfieri and his group (33) reported
esults with edge-to-edge repair in 851 patients with
evere MR with anterior leaflet MVP (Alfieri procedure),
uadrangular resection of posterior leaflet (PL) MVP; all
ad concomitant annuloplasty procedure (Table 5) per-
ormed from 1991 to April 2004 (Fig. 8). Three patients
eed reoperation in the anterior leaflet group because of
/4 MR.
omment. This was a comparatively younger age group; at
aseline about one-third were asymptomatic and about
ne-third had mild symptoms. Follow-up echocardiogram
n PL group was available in 172 of 605 (28.5%).
David et al. (34) reported 701 patients had MVrep for
>10 EFU Versus <10 EFU
. (18).F of
et alVP. Ninety-two (13%) age 53.3 years had AL prolapse,
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Year in Valvular Heart Disease January 23, 2007:361–7459 (51%) age 60.4 years had PL prolapse, and 250 (36%)
ge 56.4 years had bileaflet prolapse. Preoperatively, 14.7%
nd 32.8% were in NYHA functional class I and class II.
he operative mortality was 0.01% (5 of 701). Five-year
urvival was 75 3%. At 12 years, the recurrence rate of 3
r 4 MR was 27  3%; it was lowest in those with PL
rolapse (Fig. 9). Note that the severity of preoperative MR
as not reported.
omment. These 2 studies in patients with MVP docu-
ent the recurrence rate of 3 or 4 MR after MVrep is
ow on long-term follow-up, and the available data show
ong-Term Outcome After Aorticalve Replacement for Aortic Regurgitation
Table 3 Long-Term Outcome After AorticValve Replacement for Aortic Regurgitation
Group A
(“Early” Surgery)
Group B
(“Too Late” Surgery) p Value
Patient, n 60 110 —
Hospital mortality 3 (5%) 9 (8%) 0.5
Later mortality 7/57 (12%) 37/101 (37%) 0.001
Survival*(%) at:
5 yrs 90 4 75 8
10 yrs 86 5 64 5
15 yrs 78 7 53 6 0.009
LVEDD (mm)
Preoperative 71 7 75 8 0.001
Postoperative (1 yr) 53 6 59 12 0.0001
p Value 0.0001 0.0001
LVESD (mm)
Preoperative 48 6 55 10 0.0001
Postoperative (1 yr) 38 6 44 14 0.0001
p Value 0.0001 0.0001
LVEF (%)
Preoperative 54 7 42 10 0.0001
Postoperative (1 yr) 57 9 47 16 0.0001
p Value 0.023 0.0001
Preoperative NYHA
functional class
I 43% 25%
II 57% 15%
III — 32%
IV — 29%
End of follow-up NYHA
functional class
I 92% 72%
II 8% 21%
III — 7%
IV — —
Best-case scenario: 2 patients lost to follow-up considered to be alive. Data from Tornos et al. (21).
LVEDD left ventricular end-diastolic dimension; LVEF left ventricular ejection fraction; LVESD
eft ventricular end-systolic dimension; NYHA  New York Heart Association.
utcomes in 132 Asymptomatica ients With Severe Mi ral Regurgitation
Table 4 Outcomes in 132 AsymptomaticPatients With Severe Mitral Regurgitation
Time of Follow-Up Survival* Event-Free Survival*
2 yrs 99 1% 92 2%
4 yrs 96 2% 78 4%
6 yrs — 65 5%
8 yrs 91 3% 55 6%Thirty five patients had surgery. Data from Rosenchek et al. (32).ood patient outcomes were much better and have impli-
ations for percutaneous procedures (see the following text).
hese data also suggest that aggressive treatment with
Vrep (in centers with experience and skill for MVrep) is
ppropriate in patients who fulfill the criteria used in the
ienna study (see the preceding text).
R: Ischemic
V in end-stage heart failure are not normal. Mitral
alve leaflets and chordae from transplant recipient hearts
Figure 7 Actuarial Event-Free Survival in Asymptomatic
Patients With Severe Mitral Valve Regurgitation
(A) Kaplan-Meier event-free survival for asymptomatic patients with mitral valve
prolapse; (n  74) versus flail leaflet (n  58), p  0.23. (B) Kaplan-Meier
survival free of various events. From Rosenchek et al. (32).
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January 23, 2007:361–74 Year in Valvular Heart Disease11 with dilated and 12 with ischemic cardiomyopathy)
ere mechanically tested (35). Radially oriented anterior
V leaflets were on average 61% stiffer and 23% less
iscous than those from autopsy control hearts. The
tiffness of circumferentially oriented anterior MV leaflets
as also 50% higher. Leaflet extensibility was reduced by
5%, and failing chordae were 16% stiffer. The p value for
ll was 0.05.
omment. Changes described complement the previous
tudy of the authors that documented biochemical and
tructural derangements in the extracellular matrix of such
alves (36).
xercise-induced increase in effective regurgitant orifice
ERO) (>13 mm) is predictor of worse outcome. A total
f 161 patients with at least mild MR were followed for 35
11 months; of whom, 20 underwent surgery. Of the
emaining 141 patients treated medically, 23 died, 22
equired hospitalization for heart failure, 4 had non-fatal
yocardial infarction, and 11 developed unstable angina
37). By multivariate analysis, an exercise-induced increase
f ERO 13 mm2 and a greater increase in transtricuspid
ressure gradient were predictors of mortality and of hos-
ital admission for heart failure. An ERO 20 mm2 at rest
as an independent predictor of only cardiac death. For all
61 patients, besides ERO, greater increase of LV volumes
t rest and a decrease or small increase of LVEF were also
redictors of poor outcome.
eneficial effects of autologous skeletal myoblasts
ransplantation. Two months postmyocardial infarc-
ion, sheep were randomized to culture medium only (n
7) or autologous skeletal myoblasts (n  6) (38). At
acrifice, transplanted animals showed beneficial effects
aseline Data and Outcomes inti nts Undergoing Mitral Valve Repair
Table 5 Baseline Data and Outcomes inPatients Undergoing Mitral Valve Repair
Anterior Leaflet
Prolapse
Posterior Leaflet
Prolapse
Patients, n 133 605
Age, yrs 53.7  14.8 54.1  13.8
NYHA functional class I 36.4% 38.5%
NYHA functional class II 32.3% 32.8%
Atrial fibrillation 20% 18%
Hospital mortality 0% 0.3%
Follow-up complete 100% 97.2%
Survival
10 yrs 91  4.06% 93.5  1.81%
Freedom from:
Cardiac death 95.8  2.83% 97.4  0.95%
Re-operation 96  2.3% 96.5  1.18%
NYHA functional class I/II 93.2% 92.8%
MR grade
0/4 39% 37.7%
1/4 51.1% 53.4%
2/4 7.5% 8.7%
ata from DeBonis et al. (33).
MR  mitral regurgitation; NYHA  New York Heart Association.Table 6).ricuspid Valve
ricuspid valve replacement (TVR). Tricuspid valve re-
lacement was performed in 138 patients (103 mechanical,
5 bioprosthetic valves) (39). Tricuspid valve replacement
as isolated in 41. In-hospital and late deaths were 17.6%
nd 10.4%, respectively. At 15 years, survival was 73.8 
.5%, freedom from reoperation was 66.3  9.4%, and
reedom from valve-related events was 49.9  8%. The
inearized incidence of valve thrombosis was 1.92% per
atient year with mechanical valve.
Tricuspid valve replacement was performed in 81 patients
etween 1985 and 1999, isolated in 25. Mean age was 61
ears, NYHA functional class III to IV in 90%, urgent/
mergent in 76%. Tricuspid regurgitation was functional in
2%, organic in 64%, and failed valve repair 14% (40).
perative mortality was 22%. Survival at 5 and 10 years was
0% and 45% for bioprosthesis and 69% and 59% with
echanical valves.
omment. Even 46 years after start of valve replacement, the
esults of TVR are not as good as after AVR or even MVR;
perative mortality is higher, and late survival is worse. After
VR comparison of outcomes between the 2 types of valves
howed the incidence of thrombosis of mechanical valves is
igher and the rate of structural valve deterioration (SVD) of
ioprosthesis is higher. Better valves, valve repair techniques,
riteria to select patients for surgery, and timing of surgery are
eeded. Is there a role for percutaneous valve implantation
please see the following text)?
nfective Endocarditis (IE)
revalence. From 1970 to 2000, the prevalence of age
nd gender-adjusted IE ranged from 5.0 to 7.0 cases per
00,000, which did not change significantly over time
Figure 8 Actuarial Overall Freedom From Reoperation
ALP  anterior leaflet prolapse; PLP  posterior leaflet prolapse.
From De Bonis et al. (33).
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Year in Valvular Heart Disease January 23, 2007:361–74p  0.42 for trend) in residents of Olmstead County,
innesota (41). Streptococcus viridians was the most com-
on infecting organism (1.7 to 3.5 cases/100,000) and that
ue to Staphylococcus aureus was the next most common (1.0
o 2.2 cases/100,000). There was a trend of increasing IE in
eople with MVP (p  0.04).
rognostic value of echocardiography. Four centers pro-
pectively identified 384 consecutive patients with IE, all of
hom had TTE and TEE echocardiographic studies from
993 to 2003 (42). Embolism events (EE) occurred in 131
atients (34.1%) of whom 28 (7.3%) had an embolus after
nitiation of antibiotic therapy (new embolism events).
. aureus and Streptococcus bovis were independently associated
ith embolism events whereas vegetation length10 mm and
severe” vegetation mobility were predictors of new embolism
vents even after adjustment for S. aureus and S. bovis.
ne-year mortality was 20.6%. In multivariate analysis, vege-
ation length 15 mm was a predictor of 1-year mortality
adjusted relative risk 1.8, p  0.02) independent of other
redictors of death and of co-morbidity.
etter outcomes after MVrep. Thirty-four IE patients,
ge 51.5  17 years, Euro score 9.8  4.2 had MVrep and
4 patients, age 53.2 13.1 years, Euro score 9.7 3.8 had
VR (43). Mitral valve repair versus MVR operative
ortality was the same (11.8%) whereas event-free survival
t 5 years was 80.4% versus 54.6%, p  0.015. By multi-
ariate analysis, patients who had MVrep had better 5-year
urvival (hazard ratio 0.33, p  0.02).
etter outcome with surgery for prosthetic valve endo-
arditis (PVE). Early PVE (n 20) and late PVE (n 84)
ere associated with an in-hospital mortality of 30% and 19%,
espectively (44) (p  0.43) and a later mortality of 30% and
9%, respectively (p  0.07). Surgical therapy was associated
ith a better survival in 2 subgroups: 1) in 25 patients with
taphylococcal PVE, in-hospital mortality was lower with
urgery 27% versus 73% for medical therapy alone, p  0.03,
nd also lower at late follow-up, p 0.03; and 2) in 69 patients
Figure 9 Freedom From Recurrent Moderate or Severe MR
in Patients with PL, AL, and BL Prolapse
AL  anterior leaflet prolapse; BL  bileaflet prolapse; MR  mitral
regurgitation; PL  posterior leaflet prolapse. From David et al. (34).ith complicated PVE, in-hospital mortality was lower with murgery 18% versus 48% for medical therapy, p 0.05, and also
ower at late follow-up, p  0.001.
omment. Figures show almost all the benefit of better
urvival was due to lower in-hospital mortality.
uropean Society of
ardiology Recommendations
he European Society of Cardiology recommendations
elate to management of patients after heart valve surgery
45); competitive sports participation in athletes with car-
iovascular disease (46).
Newer” Interventional Therapeutic Procedures
ff-pump surgical MV implantation. Off-pump, trans-
trial mitral valve implantation with stented Medtronic (Min-
eapolis, Minnesota) Mosaic bioprosthesis through an open-
ng in the atrial wall attempted in 6 sheep was successful in 5
47). Left atrial and LV end-diastolic pressures were elevated.
eft ventricular angiogram showed no MR (Fig. 10). The
nimal with the better hemodynamics was kept alive and was
till alive 3 months after implantation.
omment. An interesting development by Bonhoeffer who
as the first with percutaneous valve implantation pulmo-
ary in 2000 (48). Mitral valve implantation is not percu-
aneous yet. Tricuspid percutaneous prosthetic heart valve
PHV) might be the next step because percutaneously it is
ore easily accessible than the mitral and the results of
urgical TVR are still not as good as after surgical AVR or
VR (see the preceding text).
ulmonary percutaneous valve implantation. Pulmonary
ercutaneous valve implantation was successful in 58 of 59
atients, median age 16 years, median weight 56 kg after repair
f congenital heart disease (48). There were significant reduc-
ions of right ventricular (RV) pressure, RV outflow tract
radients, pulmonary regurgitation, regurgitant fraction, and
V end-diastolic volume and increases of LV end-diastolic
olumes, RV stroke volume, and of maximumVO2 on exercise.
ransapical AV implantation. An emaciated, 52 kg, 75-
ear-old woman in congestive heart failure had calcific AS
ith 54 mm Hg mean gradient, AVA 0.4 cm2 and LVEF
.35 (49). At surgery, with portable C-arm providing
uoroscopy and anterolateral thoracotomy, the heart was
xposed and pericardium opened. A stiff 24-F valve delivery
heath was introduced into the LV and the Cribier valve
eneficial Effects 2 Months After Autologuskel tal Myoblas Transplantation in Experimental Sheep
Table 6 Beneficial Effects 2 Months After AutologusSkeletal Myoblasts Transplantation in Experimental Sheep
Control
Group
Transplanted
Group p Value
Reduced MR progression (ml) 59 0.7 1.83 0.32 0.0001
Tethering distance (cm) 0.44 0.12 0.41 0.09 0.001
Improvement in LVEF (%) 4.86 2.23 2.01 0.94 0.02
Wall motion score index 0.13 0.03 0.25 0.11 0.01
Increase of LVESV (ml) 35.4 4.2 23.3 3.5 0.055
ata from Messas et al. (38).
LVEF  left ventricular ejection fraction; LVESV  left ventricular end-systolic volume; MR 
itral regurgitation.
(
t
p
1
h
P
A
y
s
v
a
f
d
A
T
E
9
e
f
i
C
r
r
P
P
T
F
f
t
M
p
b
m
i
w
e
f
1
w
u
d
f
P
t
a
i
b
3
a
2
1
P
p
s
d
f
c
0
p
d
d
p
4
P
V
y
a
(
n
w
r
371JACC Vol. 49, No. 3, 2007 Rahimtoola
January 23, 2007:361–74 Year in Valvular Heart DiseaseEdwards Lifesciences, Irvine, California) was implanted in
he AV. The patient was well and able to walk on the third
ostoperative day and discharged home on the ninth day. At
month, AVA was 1.7 cm2; at 2 months patient was not in
eart failure.
ercutaneous retrograde AV implantation. Percutaneous
V implantation was attempted in 18 patients (age 81  6
ears) in whom surgical risk was deemed excessive. After
uccessful percutaneous valve implantation with the Cribier
alve (Edward Lifesciences) in 14 patients, which was
pproved for compassionate clinical use, AVA increased
rom 0.6  0.2 to 1.6  0.4 cm2. At follow-up of 75  55
ays, 16 of 18 patients (89%) were alive (50).
V implantation for calcific AS: “mid-term” follow-up.
his is an additional report of the “initial feasibility studies.”
leven of 27 patients were alive at follow-up ranging from
months (n  2) to 26 months (n  2). All patients
xperienced amelioration of symptoms (90% in NYHA
unctional class I/II) (51). PHV remained unchanged dur-
ng follow-up, and “no deaths were device related.”
omment. A multicenter study that included this group
eported 3 or 4 AR in 21 of 41 (51%) patients who had
eceived the 23-mm PHV and 0 of 4 patients with 26-mm
HV (52).
ercutaneous MVrep using edge-to-edge technique.
wenty-seven patients had a 6-month follow-up in the
ood and Drug Administration-approved phase I safety and
easibility trial (EVEREST) (53). Patients had moderate-
o-severe or severe MR, and all patients were candidates for
V surgery in the event that it was required for managing
otential complications. Patients were selected if they met
asic criteria for intervention according to guideline recom-
endations. Ninety-three percent had “degenerative” and 7
schemic etiology for the MR. A total of 85% (23 of 27)
ere free of major adverse event at 30 days; the 4 major
vents were permanent stroke in 1 and clip detachment
Figure 10 Angiograms After Transatrial Insertion of Collapsible
(A) Aortogram showed no aortic regurgitation. (B) Left ventriculogram showed no mitrrom 1 leaflet in 3. At 1 month, MR was 2 in 14, and b3 of 14 maintained that MR at 6 months. Three patients
ith partial clip detachment and another patient with
nresolved MR underwent MV surgery; among patients
ischarged from the hospital with a clip in place, freedom
rom valve surgery at 6 months was 18 of 22 (82%).
ercutaneous transvenous mitral annuloplasty. Five pa-
ients, age 67  10 years underwent transvenous mitral
nnuloplasty with the Edwards system which was successful
n 4 (54). There was one late death at day 148. Values at
aseline and at 3 months for mitral annular diameter were
6  3 mm and was 35  1 mm; LVEFs were 42  11%
nd 50  6%; NYHA functional classes were 2.4  0.5 and
.0  0.7. Baseline MR grade was 3.0  0.7 and was grade
.6  1.1 at the last postprocedural visit.
ercutaneous septal sinus shortening. New percutaneous
rocedure was developed that allows for shortening of the
eptal-to-lateral (SL) mitral annular diameter. Sheep un-
erwent rapid RV pacing to obtain moderate-to-severe
unctional MR (55). Postimplantation SL diameter de-
reased in 19 sheep from 32.5 3.5 to 24.6 2.4 mm, p
.001, and MR was reduced from 2.1  0.6 to 0.2  0.4,
 0.001. At 30 days, in 4 animals, SL diameter had
ecreased from 30.4 1.9 to 23.9 0.5, p 0.01, MR was
ecreased from 1.8  0.5 to 0.2  0.1, p  0.01, and mean
ulmonary artery wedge pressure was reduced from 23.9 
.1 to 13.8  2.2 mm Hg (p  0.01).
rosthetic Heart Valves
ery impressive long-term results of mechanical MVR in
oung women. Two-hundred sixty seven patients, age
bout 31 7 years, received caged ball (n 73), tilting disc
n  133), or bileaflet (n  61) PHV. The international
ormalized ratio (INR) was 3.0 to 4.0 with caged ball and
ith tilting disc (79.4% of those with caged ball also
eceived aspirin 100 mg/day) and was 2.5 to 3.5 with
e Stent
rgitation and no evidence of subaortic stenosis. From Boudjemline et al. (47).Valv
al reguileaflet PHV (56). Thirty-day mortality was 1.1%.
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Year in Valvular Heart Disease January 23, 2007:361–74wenty-five-year results are shown in Table 7. Atrial
brillation was an independent risk factor for mortality, and
VEF was protective for mortality. Atrial fibrillation and
arbomedics valve were predictors for thromo-emboli, and
ilting disc was a predictor of reoperation. At end of study,
08 of 267 (78%) were still alive; 61.1% and 33.6% were in
YHA functional class I and II, respectively.
When receiving warfarin therapy, 35 patients under-
ook 46 pregnancies and none (0) experienced adverse
ardiac- or valve-related events. There were 27 healthy
abies, 16 spontaneous abortions, 2 stillbirths, and 1 had
entricular septal defect. Fetal events were less frequent
ith a daily warfarin dose 5 mg (p  0.001). Two
atients treated with heparin after “general practitioner
ounseling” experienced valve thrombosis necessitating
urgery and had perioperative abortion. With regard to
arfarin-treated subset, INR was estimated weekly, no
atient experienced adverse cardiac- or valve-related
vents during child bearing.
andomized trials of PHV hemodynamics. There was no
ignificant difference in 16 patients at 3 to 6 months and at
-year in AVA index (cm2/m2) between the Toronto
tentless (St. Jude Medical, St. Paul, Minnesota) porcine
alve and the PERIMOUNT stented bovine pericardial
alve (Edwards Lifesciences) (Table 8) (57). At 1 year, there
as a decrease in LV mass index (g/m2) of 11% from 224 to
77 g/m2 in the Toronto stentless and of 20% from 249 to
82 g/m2 for the PERIMOUNT (p  0.21).
At hospital discharge, the AVA index (cm2/m2) of the
arpentier-Edwards PERIMOUNT Magna 1.07  0.4 was
reater than that of the Carpentier-Edwards PERIMOUNT
0.80 0.2) or the Edward Prima Plus (Edwards Lifesciences)
0.87  0.3) (p  0.028) (58).
omment. Other randomized trials of PHV areas be-
ween the PERIMOUNT and Toronto Stentless and the
5-Year Results With Use of Mechanicalitral Prosthetic Heart Valve in You g Women
Table 7 25-Year Results With Use of MechanicalMitral Prosthetic Heart Valve in Young Women
Follow-Up
Time (yrs)
Survival
(%)
Thromboembolism
(%)
Re-Operation
(%)*
1 97 0.01 2 0.01 —
5 90 0.02 16 0.02 1 0.005
10 85 0.02 11 0.02 5 0.02
15 82 0.03 14 0.03 8 0.02
20 72 0.04 19 0.03 11 0.02
25 70 0.04 25 0.06 14 0.04†
Value for one time not presented in text/abstract; assumed it was for 1-year follow-up; †incidence
as 0.8% patient per year. Note: values are rounded off. Data from DeSanto et al. (56).
Randomized Trial of Toronto Stentless and Perim
Table 8 Randomized Trial of Toronto Stentle
Time
Sub-Coronary
Toronto Stentless*
At surgery, size (mm) 24.7 2.69
3–6 months postop (cm2/m2) 0.89 0.26
1-yr postop (cm2/m2) 0.88 0.22*All values of valve size are mean  SD. Data from Chambers et al. (57).
CI  confidence interval.ERIMOUNT (Edwards Lifesciences) and Medtronic
osaic were described earlier (2,59).
igher late mortality with severe valve prosthesis-patient
ismatch (VP-PM). Three hundred eighty-eight patients,
ge 62  13 years, had AVR with a 19- or 21-mm St. Jude
edical prosthesis from 1985 to 2000. PHV index was
alculated from the first postoperative TTE within 1 year
60). Patients with severe VP-PM (AVA index 0.6
m2/m2, n 66) had a significantly higher body surface area
.91  0.22 m2 than those with moderate VP-PM, p 
.0001. Patients with severe VP-PM had a lower 5-year
urvival (72 6%) and 8-year survival (41 8%) than those
ith moderate VP-PM (80 3% and 65 5%, p 0.026)
r mild VP-PM (85  3% and 74  5%, p  0.002). This
as true in those with 19- or 21-mm PHV. The 8-year
ncidence of congestive heart failure was significantly (p 
.02) higher in those with severe (29  8%) than with
oderate (14  3%) or mild (13  4%) VP-PM.
omment. The number of patients who had their first
ostoperative TTE in-hospital and at 6 and 12 months
ould be important to know.
VD of biological valves with follow-up >15 years. Four
undred seventy-eight patients, age 65  11 years, 138
ere 60 years, received Carpentier-Edwards pericardial
alves (PERIMOUNT, Edwards Lifesciences) and were
ollowed-up for 15  5.1 years (61). Structural valve
eterioration for pericardial valves at 15 years and 19 years
as 23% and 53%. Explantation for SVD in the pericardial
alves was low in those age 60 years.
omment. Younger patients, especially age50 years, had
much higher rate of SVD. Explantation for SVD is likely
o be lower than rate of SVD.
A total of 1,464 patients received the Mitroflow synergy
ovine pericardial valve (BC MedTech, Vancouver, Can-
da). Structural valve deterioration at 5, 10, and 15 years was
.0  0.3%, 17.2  2.2%, and 37.2  5.8%, respectively
62).
omment. Structural valve deterioration began at about 5
ears, and then increased very rapidly particularly in those
ge 70 and 70 to 74 years. There were few patients at risk
t 15 years.
A total of 1,599 patients, age 67  11 years, had PHV
ith Hancock II bioprosthesis (Medtronic) (AVR in 1,010
atients and MVR in 559 patients) (63). After AVR, the
ate of SVD in those age 65 years versus those 65 years
t 10 years was 6  2% versus 1  1%, respectively, and at
0 years was 61  9% versus 27  16%, respectively. After
Prosthetic Heart Valves
d Perimount Prosthetic Heart Valves
Supra-Annular
Perimount*
95% CI of the
Difference p Value
24.7 2.17 — —
0.90 0.26 0.10 to 0.07 0.775
0.90 0.26 0.11 to 0.06 0.537ount
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January 23, 2007:361–74 Year in Valvular Heart DiseaseVR, the rate of SVD in those age 65 years versus those
65 years at 10 years was 18 5% versus 5 2% and at 20
ears was 73  9% versus 41  11%.
omment. Structural valve deterioration was defined as
clinically relevant valvular stenosis or insufficiency as
etermined by Doppler echocardiography, reoperation,
r autopsy.” The number of patients and number of the
chocardiography/Doppler studies performed over time
re not described.
ther issues. VERY HIGH RATE OF BLEEDING WITH ME-
HANICAL PHV IN ELDERLY PEOPLE. A total of 392 pa-
ients, mean age 74 years, had AVR with stentless freestyle
ioprosthesis (n  247) or mechanical St. Jude prosthesis
n  145). Mean follow-up was 30  18 months (64).
here were no statistical differences in outcomes between
he 2 types of PHV. Patients 75 years with mechanical
alve had a greatly increased risk of major bleeding events
OR 18.9, 95% CI 2.2 to 163.0, p  0.007) and patients
eceiving “coumarin” had a 2-fold increased risk of an
mpaired emotional reaction (p  0.052).
EOPERATION FOR AORTIC ANEURYSM AFTER ROSS PRIN-
IPLE. Of 112 patients, 29  10 years of age, 110 had
ollow-up 5.1  1.9 years (range 0.3 to 10.6 years). At 10
ears, the incidence of aortic dilatation (diameter 4
m/0.21 cm/m2) was 29%; aortic aneurysm (5.0 cm) was
%. At 10 years, the incidence of reoperation was 19  6%,
f valve replacement 12  5%, and of any reintervention 28
10% (65).
iscellaneous
ibroelastoma. Eighty-eight patients, age 62  16 years,
ad surgery for this tumor from 1985 to 2002 (66). Cardiac
apillary fibroelastoma was a primary indication for surgery
n 47 and incidental finding in 41. Cardiac valves were
nvolved in 77%, AV in 52%, anterior leaflet of MV in 11%,
ll valves in 1.1%, and LV outflow tract in 18%. Seventy-
hree had shave excision, 8 had excision with valve repair,
nd 5 had valve replacement. With a mean follow-up of 3
ears, there was no tumor recurrence and no tumor-related
orbidity or mortality.
eprint requests and correspondence: Dr. Shahbudin H. Ra-
imtoola, University of Southern California, 2025 Zonal Avenue,
NH 7131, Los Angeles, California 90033.
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